AVA 001 - Avalon GloboCare
Alternative Names: Anti-CD19 chimeric antigen receptor T cell therapy - Avalon GloboCare; AVA-001 - Avalon GloboCareLatest Information Update: 28 Oct 2022
At a glance
- Originator Avalon GloboCare
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Recurrent, Second-line therapy or greater) in China (Parenteral)
- 28 Oct 2022 No recent reports of development identified for phase-I development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma(Recurrent, Second-line therapy or greater) in China (Parenteral)
- 13 Jul 2020 Avalon GloboCare plans a further clinical trial for AVA 001